2024 2030 China Molecular Diagnostics Industry Risk Assessment and Investment Strategy Research Report
Publisher]: Zhongying Xinhe Research Network.
The content part has been deleted and detailed can be found in the full information published by Zhongying Xinhe Research Network! 】
Chapter 1 Overview of the Molecular Diagnostics Industry.
1.1 Basic overview of in vitro diagnostics.
1.1.1 Definition of in vitro diagnostics.
1.1.2 Classification of in vitro diagnostics.
1.1.3 The life cycle of an industry.
1.2 Basic overview of molecular diagnostics.
1.2.1 Concepts and Principles.
1.2.2 Technological development history.
1.2.3. Key technical features.
Chapter 2 Analysis of the development environment of the molecular diagnostics industry from 2021 to 2023.
2.1 Economic Environment.
2.1.1 Analysis of the world economic situation.
2.1.2 Domestic macroeconomic overview.
2.1.3 Analysis of China's foreign economy.
2.1.4. Economic transformation and upgrading.
2.1.5 Future economic development trends.
2.2 Social environment.
2.2.1 Trends in population ageing.
2.2.2 Income level of residents.
2.2.3. Household consumption structure.
2.2.4 The scale of social consumption.
2.3 Policy environment.
2.3.1. Industry regulatory system and policy.
2.3.2. Industry catalogue to guide development.
2.3.3 National standards for product classification.
2.3.4 Diagnostic reagent development policy.
2.3.5. Pharmaceutical policies support development.
Chapter 3 Comprehensive Analysis of the Development of the In Vitro Diagnostics Industry from 2021 to 2023.
3.1 Global in vitro diagnostics industry market status from 2021 to 2023.
3.1.1. Market development scale.
3.1.2 Market regional distribution.
3.1.3 Segment distribution.
3.1.4. Product layout.
3.1.5. Enterprise competition pattern.
3.2 Analysis of the development of China's in vitro diagnostic industry from 2021 to 2023.
3.2.1 Status of patent applications.
3.2.2 Market development scale.
3.2.3 Segment distribution.
3.2.4 Industry revenue.
3.2.5. Capital layout.
3.3 Existing problems in China's in vitro diagnostic industry.
3.3.1. The industrial concentration is relatively low.
3.3.2. Pressure caused by bidding and procurement.
3.3.3. The overall added value of the industry is low.
3.4 Development countermeasures for China's in vitro diagnostic industry.
3.4.1. Encourage mergers and acquisitions of enterprises.
3.4.2. Improve the product registration system.
3.4.3. Support early-stage original projects.
Chapter 4 Comprehensive analysis of the development of the molecular diagnostics industry from 2021 to 2023.
4.1 Analysis of the development of the global molecular diagnostics industry from 2021 to 2023.
4.1.1 Subdivision technology patents.
4.1.2 Market development scale.
4.1.3 Market competition pattern.
4.1.4. Mergers and acquisitions.
4.2 2021-2023 China molecular diagnostics industry market operation analysis.
4.2.1. Market development scale.
4.2.2 Market competition pattern.
4.2.3 Regional market conditions.
4.2.4 Segment share.
4.2.5 Enterprise revenue.
4.2.6 Market demand application.
4.3 Problems in China's molecular diagnostics industry.
4.3.1 Policy and regulatory issues.
4.3.2 Market development issues.
4.3.3. R&D capability issues.
4.4 Development countermeasures of China's molecular diagnostics industry.
4.4.1. Macro level overall layout.
4.4.2. Improve relevant industrial policies.
4.4.3. Pay attention to the intellectual property system.
Chapter 5 Upstream and downstream analysis of the molecular diagnostics industry chain from 2021 to 2023.
5.1. The overall situation of the industrial chain.
5.1.1. Industrial chain structure.
5.1.2 Main Participants.
5.2 Upstream of the molecular diagnosis industry chain - diagnostic reagents.
5.2.1 Product standard situation.
5.2.2 Localization.
5.2.3. Project construction status.
5.3. Upstream of the molecular diagnosis industry chain - diagnostic instruments.
5.3.1. Localization of diagnostic instruments.
5.3.2. Competition in the key instrument market.
5.3.3 Impact analysis of upstream industries.
5.4. Downstream of the industry - medical institutions and independent medical laboratories.
5.4.1 The number and scale of medical institutions in the country.
5.4.2 Scale of development of independent medical laboratories.
5.4.3 Competition in the independent medical laboratory market.
5.4.4. Analysis of the impact of downstream industry development.
Chapter 6 Comprehensive Analysis of the Development of Molecular Diagnostic Technology from 2021 to 2023.
6.1 Fluorescence in situ hybridization technique.
6.1.1 Basic Concepts.
6.1.2 Technological development.
6.1.3 Technical advantages.
6.1.4 Application of Technology.
6.2 Gene chip technology.
6.2.1 Basic technical concepts.
6.2.2 Market development scale.
6.2.3 Application of technology.
6.2.4. Industry competition pattern.
6.2.5 Future development trends.
6.3 Polymerase chain reaction technology.
6.3.1 Basic technical concepts.
6.3.2 Enterprise Competitive Landscape.
6.3.3 Subdivision of technology development.
6.3.4. Key technology applications.
6.4 Gene sequencing technology.
6.4.1 Basic technical concepts.
6.4.2 Comparison of sequencing technologies.
6.4.3. Market development scale.
6.4.4 Main technical applications.
6.4.5 Financing status of the industry.
6.4.6 Future Trends.
6.5 Molecular diagnostic characteristic detection technology in China.
6.5.1 One-step PCR detection technology.
6.5.2 Super-Arms PCR technology.
6.5.3. Integrated automation and microfluidic technology.
6.5.4 Magnetic bead-based PCR detection technology with magnetic bead amplification.
Chapter 7 Market Analysis of Major Applications of Molecular Diagnostics from 2021 to 2023.
7.1 Non-invasive prenatal testing (NIPT).
7.1.1 Basic Overview.
7.1.2 Technical advantages.
7.1.3 **Support Policy.
7.1.4. Market development scale.
7.1.5 Competitive Landscape.
7.2 Companion diagnostics (CD).
7.2.1 Basic Overview.
7.2.2 Demand influencing factors.
7.2.3. Market development scale.
7.2.4 Market competition pattern.
7.3. Early tumor screening.
7.3.1 Basic Concepts.
7.3.2 Policy support.
7.3.3 Competitive landscape.
7.3.4 Key projects.
7.4 COVID testing.
7.4.1 Demand influencing factors.
7.4.2 Proportion of technology applications.
7.4.3. Market development space.
7.4.4 Enterprise revenue.
7.5 Blood screening.
7.5.1 Basic Concepts.
7.5.2 Enablers.
7.5.3 Competitive landscape.
7.5.4 Scale**.
7.6 Consumer-grade genetic testing.
7.6.1 Basic Overview.
7.6.2 Degree of market penetration.
7.6.3 Market competition pattern.
Chapter 8 Analysis of Key Enterprises in Foreign Molecular Diagnostics Industry from 2021 to 2023.
8.1 Roche Group
8.1.1. Overview of enterprise development.
8.1.2 Analysis of business conditions in 2021.
8.1.3 Analysis of business conditions in 2022.
8.1.4 Analysis of business conditions in 2023.
8.2 Novartis
8.2.1. Overview of enterprise development.
8.2.2 Analysis of business conditions in 2021.
8.2.3 Analysis of business conditions in 2022.
8.2.4 Analysis of business conditions in 2023.
8.3 gen-probe
8.3.1. Overview of enterprise development.
8.3.2 Analysis of business conditions in 2021.
8.3.3 Analysis of business conditions in 2022.
8.3.4 Analysis of business conditions in 2023.
8.4 cepheid
8.4.1. Overview of enterprise development.
8.4.2 Analysis of business conditions in 2021.
8.4.3 Analysis of business conditions in 2022.
8.4.4 Analysis of business conditions in 2023.
8.5 BD
8.5.1. Overview of enterprise development.
8.5.2 Analysis of business conditions in 2021.
8.5.3 Analysis of business conditions in 2022.
8.5.4 Analysis of business conditions in 2023.
Chapter 9 Business Analysis of Key Enterprises in China's Molecular Diagnostics Industry from 2020 to 2023.
9.1 Shenzhen BGI Technology***
9.1.1. Overview of enterprise development.
9.1.2. Analysis of business benefits.
9.1.3 Business operation analysis.
9.1.4 Analysis of the financial situation.
9.1.5. Core competitiveness analysis.
9.1.6 The company's development strategy.
9.1.7 Future prospects.
9.2 Sun Yat-sen University Da'an Gene Co., Ltd. ***
9.2.1. Overview of enterprise development.
9.2.2. Analysis of business benefits.
9.2.3 Business operation analysis.
9.2.4 Analysis of the financial situation.
9.2.5. Core competitiveness analysis.
9.2.6 The company's development strategy.
9.2.7 Future prospects.
9.3 Beijing Berry and Kang Biotechnology***
9.3.1. Overview of enterprise development.
9.3.2. Analysis of business benefits.
9.3.3 Business operation analysis.
9.3.4 Analysis of the financial situation.
9.3.5. Core competitiveness analysis.
9.3.6 The company's development strategy.
9.3.7 Future prospects.
9.4 Shanghai Toujing Life Science and Technology Co., Ltd. ***
9.4.1. Overview of enterprise development.
9.4.2. Analysis of business benefits.
9.4.3 Business operation analysis.
9.4.4 Analysis of the financial situation.
9.4.5. Core competitiveness analysis.
9.4.6 The company's development strategy.
9.4.7 Future prospects.
9.5 Shanghai Kehua Bioengineering Co., Ltd. ***
9.5.1. Overview of enterprise development.
9.5.2. Analysis of business benefits.
9.5.3 Business operation analysis.
9.5.4 Analysis of the financial situation.
9.5.5. Core competitiveness analysis.
9.5.6 The company's development strategy.
9.5.7 Future prospects.
9.6 Guangdong Kaipu Biotechnology Co., Ltd. ***
9.6.1. Overview of enterprise development.
9.6.2. Analysis of business benefits.
9.6.3 Business operation analysis.
9.6.4 Analysis of the financial situation.
9.6.5. Core competitiveness analysis.
9.6.6 The company's development strategy.
9.6.7 Future prospects.
9.7 Anhui Anke Bioengineering Co., Ltd. ***
9.7.1. Overview of enterprise development.
9.7.2. Analysis of business benefits.
9.7.3 Business operation analysis.
9.7.4 Analysis of the financial situation.
9.7.5. Core competitiveness analysis.
9.7.6 The company's development strategy.
9.7.7 Future prospects.
9.8 Xiamen Zhishan Biotechnology Co., Ltd. ***
9.8.1. Overview of enterprise development.
9.8.2. Analysis of business benefits.
9.8.3 Business operation analysis.
9.8.4 Analysis of the financial situation.
9.8.5. Core competitiveness analysis.
9.8.6 The company's development strategy.
9.8.7 Future prospects.
Chapter 10 Investment Analysis of China's Molecular Diagnostics Industry from 2021 to 2023.
10.1 Analysis of the driving factors of China's molecular diagnostics industry.
10.1.1. Policies drive development.
10.1.2 The need for efficacy improvement.
10.1.3 Reduced cost of testing.
10.1.4 Increased capital inflows.
10.2 Analysis of investment and financing situation and investment ideas in the molecular diagnosis industry.
10.2.1 Industry financing.
10.2.2 IPO of enterprises.
10.2.3 Financing in subdivisions.
10.2.4. Analysis of investment ideas.
10.3 Analysis of investment barriers in China's molecular diagnostics industry.
10.3.1 Technical barriers.
10.3.2 Financial barriers.
10.3.3. Talent barriers.
10.3.4 Brand barriers.
10.4 Investment risk warning of China's molecular diagnostics industry.
10.4.1 Policy risk.
10.4.2 Technical Risks.
10.4.3 Market Risk.
10.4.4 Product Risks.
Chapter 11 Analysis of the development prospects and trends of China's molecular diagnostics industry from 2024 to 2030.
11.1 Development trend of China's molecular diagnostic industry.
11.1.1. The direction of industry development.
11.1.2 Industry Competitive Trends.
11.1.3 Application development direction.
11.2 Prospects for the development of China's molecular diagnostics industry.
11.2.1. Industry mergers and acquisitions are accelerating.
11.2.2. Product application optimization.
11.3 Zhongying Xinhe's analysis of China's molecular diagnostic industry from 2024 to 2030.
11.3.1 Analysis of influencing factors of China's molecular diagnostics industry from 2024 to 2030.
11.3.2 Global molecular diagnostics market size 2024-2030**.
11.3.3 China Molecular Diagnostics Market Size, 2024-2030**.
Table of Contents of Charts. Chart Classification of the main methods of in vitro diagnosis and their advantages and disadvantages.
Chart Technology Life Cycle of China's IVD Industry.
Chart The development history of molecular diagnostics technology.
Chart: Advantages and disadvantages of each key technology and main application areas of molecular diagnostics.
Chart GDP and its growth rate 2018-2022.
Chart Proportion of added value of the three industries to GDP from 2018 to 2022.
Chart Total imports and exports of goods, 2018-2022.
Chart Total imports and exports of goods and their growth rate in 2022.
Chart The volume, value and growth rate of exports of major commodities in 2022.
Chart The volume, value and growth rate of imports of major commodities in 2022.
Chart The value, growth rate and proportion of imports and exports of goods to major countries and regions in 2022.
Chart FDI and its growth rate in 2022.
Chart Outward non-financial direct investment (FDI) and its growth rate in 2022.
Chart 2018-2022 Total industrial added value and its growth rate.
Chart Output of major industrial products and their growth rate in 2022.
Chart: The year-on-year growth rate of the added value of industrial enterprises above designated size in 2023.
Chart Main data of industrial production above designated size in 2023.
Chart: The proportion of investment in the three industries in fixed assets (excluding rural households) in 2021.
Chart: Growth rate of fixed asset investment by industry (excluding rural households) in 2021.
Chart In 2021, fixed asset investment added major production and operation capacity.
Chart: The proportion of investment in the three industries in fixed assets (excluding rural households) in 2022.
Chart: Growth rate of fixed asset investment (excluding rural households) by industry in 2022.
Chart In 2022, investment in fixed assets added major production and operational capacity.
Chart The proportion of investment in the three industries in fixed assets (excluding rural households) in 2023.
Chart Growth rate of fixed asset investment (excluding rural households) by industry in 2023.
Chart Investment in fixed assets in 2023 added major production and operation capacity.
Chart: Average and median per capita disposable income of residents in China in 2020.
Chart: Average and median per capita disposable income of residents in China in 2021.
Chart 2018-2022 National per capita disposable income and its growth rate.
Chart Per capita consumption expenditure and composition in 2021.
Chart: National per capita consumption expenditure and its composition in 2022.
Chart: Per capita consumption expenditure and composition in 2023.
Figure Classification criteria for in vitro diagnostic reagents.
Chart Summary of policies related to in vitro diagnostic reagents in 2022.
Figure 2013-2022 global in vitro diagnostics market size and growth rate.
Chart: Global In Vitro Diagnostics Market Size Percentage and **.
Chart Market share of global in vitro diagnostics industry segment in 2020.
Chart Layout of in vitro diagnostic products at home and abroad.
Chart Competitive landscape of companies in the global in vitro diagnostics market.
Figure Number of patent applications and publications in China's in vitro diagnostic industry from 1999 to 2020.
Figure 2015-2021 market size of China's in vitro diagnostic industry.
Figure 2020 China's in vitro diagnostics market share.
Chart Revenue, profit and growth rate of China's in vitro diagnostic enterprises.
Chart 2019-2020 gross profit margin, R&D proportion and asset impairment loss ratio of China's in vitro diagnostic enterprises.
Chart Number of A-share listed companies in vitro diagnostics in China from 2019 to 2020.
Chart 2019-2020 total market capitalization of China's in vitro diagnostic A-share listed companies.
Figure Number of initial registration applications for in vitro diagnostic reagents accepted from 2017 to 2021.
Figure Number of valid patents for global nucleic acid detection technology from 2001 to 2021.
Figure Number of biochip-related patent publications worldwide, 2006-2021.
Figure 2013-2021 global molecular diagnostics industry market size and growth rate.
Chart Global Molecular Diagnostics Market Competitive Landscape.
Figure 2014-2021 China's molecular diagnostics industry market size and growth rate.
Figure 2020 China's molecular diagnostics market competitive landscape.
Chart: Market share of different technologies in molecular diagnostics in China.
Chart Revenue, profit and growth rate of China's molecular diagnostic enterprises.
Chart The industrial chain structure of molecular diagnostics.
Chart Product standards for reagents in the field of molecular diagnostics.
Chart Baishan City's annual output is 2Summary of the total investment of 50,000 boxes of molecular diagnostic reagents.
Chart Baishan City's annual output is 2The main financial benefit of the 50,000 boxes of molecular diagnostic reagent project is ** indicator.
Chart Localization of upstream equipment for molecular diagnostics in China.
Chart Approval of domestic gene sequencer.
Chart China sequencer R&D manufacturer.
Figure Global high-throughput sequencing market competition in 2020.
Chart Competitive landscape of China's gene sequencer market.
Chart The main companies involved in digital PCR at home and abroad.
Figure Number of medical and health institutions and beds in China, 2019-2020.
Figure Number of hospitals, community health service centers (stations) and township health centers in China from 2016 to 2021.
Figure Number of medical and health institutions and beds in China, 2020-2021.
Figure Number of health technicians in the country from 2016 to 2021.
Figure Number of health personnel in the country, 2020-2021.
Figure Number of personnel in various types of medical and health institutions in China from 2020 to 2021.
Chart: Diagnosis and treatment volume of medical and health institutions in China from 2016 to 2021.
Chart 2020-2021 National Medical Service Workload.
Figure Number of hospitalizations in medical and health institutions nationwide, 2016-2021.
Figure 2021-2022 National Medical Service Volume of Medical and Health Institutions.
Figure 2022 Medical Service Volume of Hospitals and Township Health Centers by Region.
Figure 2020-2021 Hospital physician workload.
Chart Total national health expenditure, 2020-2021.
Figure The number of beds in medical and health institutions in China and its growth rate from 2016 to 2021.
Figure Hospital bed usage, 2020-2021.
Chart 2021-2022 hospital bed usage.
Figure Number of independent medical laboratories in China, 2012-2020.
Chart: Cooperation between leading ICL enterprises and leading companies.
Chart: Market share of Chinese ICL companies in 2021.
Chart China's major ICL revenue and growth rate from 2014 to 2021.
Figure Schematic diagram of microarray detection.
Chart The development history of China's gene chip technology industry.
Figure 2014-2020 China's gene chip industry market size and growth rate.
Figure Application fields of gene chips.
Chart: Some of China's Gene Chip Listed Companies.
Figure Schematic diagram of the principle of PCR technology.
Diagram of PCR assay flow chart.
Chart Competitive landscape of qPCR in different application segments.
Chart Comparison of PCR detection kits covered by major molecular diagnostic companies in China.
Chart PCR breaks down the technology life cycle.
Chart Comparison of the three generations of PCR technology.
Figure Distribution of PCR products approved by NMPA.
Chart Statistics on the field of testing of second-generation PCR-based products approved by the NMPA.
Chart Advantages of digital PCR technology.
Chart Digital PCR market size from 2013 to 2022
Figure Development history of gene sequencing technology.
Figure Comparison of next-generation sequencing technologies.
Chart 2017-2022 China gene sequencing market size and**.
Chart NGS main application areas.
Chart The number and amount of genetic testing financing in China from 2015 to 2021.
Chart 2015-2021 China's genetic testing financing rounds.
Figure Schematic diagram of the principle of non-invasive prenatal testing.
Figure NIPT versus traditional prenatal testing diagnostic techniques.
Figure Advantages of non-invasive prenatal testing technology.
Chart NIPT-related support policies and ** in provinces and cities in China.
Chart 2019-2025 China NIPT market size and**.
Chart China's NIPT market competition landscape in 2020.
Diagram Companion diagnostic testing process.
Figure The effect of concomitant diagnosis on the objective response rate of targeted drugs.
Figure 2017-2021 Comparison of the decline rate of tumor targeted drugs** in medical insurance negotiations.
Chart 2014-2020 trastuzumab sales in China.
Chart Sales of bevacizumab in China from 2014 to 2020.
Chart Global Companion Diagnostics Market Size 2016-2023
Figure 2010-2021 China's companion diagnostics market size and growth rate.
Figure Staging comparison of 5-year survival rate of colorectal cancer in Chinese population.
Figure 2018-2021 China's early cancer screening policies.
Chart Research progress of early tumor screening products of major companies in China.
Chart Process and progress of Berry Gene Precar early screening project for liver cancer.
Chart: Winning bidders and bid-winning prices for the procurement of new crown nucleic acid detection reagents in some provinces in China.
Chart: Centralized procurement of new crown nucleic acid detection reagents** and medical insurance policies in some provinces of China.
Chart Approved COVID-19 test reagents in China by technology
Chart Approved COVID-19 nucleic acid detection reagents in China by technology
Chart year: Global COVID testing market size and**.
Chart Revenue, profit and growth rate of major new crown detection reagent manufacturers in 2020.
Figure 2014-2020 The number and growth rate of unpaid blood donations in China.
Chart China's pulp production and growth rate from 2010 to 2021.
Chart 2020-2023 China's nucleic acid testing market size and**.
Chart: The development of consumer genes in the United States and China.
Chart: 2016-2023 cumulative user scale of China's consumer genes and**.
Chart The number of enterprises established by China's consumer gene from 2013 to 2021.
Chart 2020-2021 Roche Group Comprehensive Income Statement.
Chart 2020-2021 Roche Group segment information.
Chart 2020-2021 Roche Group Revenue by Region.
Chart 2021-2022 Roche Group Comprehensive Income Statement.
Chart 2021-2022 Roche Group segment information.
Chart 2021-2022 Roche Group Revenue by Region.
Chart 2022-2023 Roche Group Comprehensive Income Statement.
Chart 2022-2023 Roche Group segment information.
Chart 2022-2023 Roche Group Revenue by Region.
Chart Novartis Comprehensive Income Statement, 2020-2021.
Chart Novartis segment data, 2020-2021.
Chart Novartis revenue by region, 2020-2021.
Chart Novartis Comprehensive Income Statement, 2021-2022.
Chart Novartis segment data, 2021-2022.
Chart Novartis revenue by region, 2021-2022.
Chart Novartis Statement of Comprehensive Income, 2022-2023.
Chart 2022-2023 Novartis segment information.
Chart 2022-2023 Novartis revenue by region.
Chart Gen-Probe Comprehensive Income Statement 2020-2021.
Chart 2020-2021 Gen-Probe Segment Data.
Chart Gen-Probe Revenue by Region, 2020-2021.
Chart 2021-2022 Gen-Probe Comprehensive Income Statement.
Chart 2021-2022 Gen-Probe Segment Data.
Chart 2021-2022 Gen-Probe Revenue by Region.
Chart Gen-Probe Comprehensive Income Statement 2022-2023.
Chart 2022-2023 Gen-Probe Segment Data.
Chart 2022-2023 Gen-Probe Revenue by Region.
Chart 2020-2021 Cepheid Comprehensive Income Statement.
Chart 2020-2021 CEPHEID Segment Data.
Chart 2020-2021 Cepheid Revenue by Region.
Chart 2021-2022 Cepheid Comprehensive Income Statement.
Chart 2021-2022 CEPHEID Segment Data.
Chart 2021-2022 Cepheid revenue by region.
Chart 2022-2023 Cepheid Comprehensive Income Statement.
Chart 2022-2023 CEPHEID Segment Data.
Chart 2022-2023 Cepheid Revenue by Region.
Chart 2020-2021 BD Comprehensive Income Statement.
Chart 2020-2021 BD segment data.
Chart 2020-2021 BD Revenue by Region.
Chart 2021-2022 BD Comprehensive Income Statement.
Chart 2021-2022 BD segment data.
Chart 2021-2022 BD Revenue by Region.
Chart 2022-2023 BD Comprehensive Income Statement.
Chart 2022-2023 BD segment data.
Chart 2022-2023 BD Revenue by Region.
Chart 2020-2023 BGI*** total assets and net assets.
Chart 2020-2023 BGI Technology*** operating income and growth rate.
Chart 2020-2023 BGI*** net profit and growth rate.
Chart: 2022 BGI*** main business by industry.
Chart: 2022 BGI***Main business by region.
Chart 2020-2023 BGI*** operating profit and operating profit margin.
Chart 2020-2023 BGI Technology *** Return on Net Assets.
Chart 2020-2023 BGI*** Short-term solvency indicator.
Chart 2020-2023 BGI*** asset-liability ratio.
Chart 2020-2023 BGI Operational Capability Indicators.
Chart 2020-2023 Daan Gene shares*** total assets and net assets scale.
Chart 2020-2023 Daan Gene Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 Daan Gene shares*** net profit and growth rate.
Chart 2022 Daan Gene Co., Ltd.***Main business by industry.
Chart 2022 Daan Gene Co., Ltd.*** main business by region.
Chart 2020-2023 Daan Gene Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 return on net assets of Daan Gene shares.
Chart 2020-2023 Daan Gene shares*** short-term solvency indicators.
Chart 2020-2023 Daan Gene shares*** asset-liability ratio level.
Chart 2020-2023 Daan Gene Co., Ltd. *** Operational Capability Indicators.
Chart 2020-2023 Berry Gene's total assets and net assets.
Chart 2020-2023 Berry Gene operating income and growth rate.
Chart 2020-2023 Berry Gene net profit and growth rate.
Chart 2022 Berry Gene's main business by industry.
Chart 2022 Berry Gene's main business by region.
Chart: 2020-2023 Berry Genomics operating profit and operating profit margin.
Chart 2020-2023 Berry Gene ROE.
Chart Berry Gene's Short-Term Solvency Index, 2020-2023.
Chart: Berry Gene's debt-to-asset ratio from 2020 to 2023.
Chart 2020-2023 Berry Gene Operational Capability Indicators.
Chart 2020-2023 Toujing Life Science Co., Ltd.*** total assets and net assets scale.
Chart 2020-2023 Perspective Life Science Co., Ltd.*** operating income and growth rate.
Chart: 2020-2023 Toujing Life Science Co., Ltd.*** net profit and growth rate.
Chart 2022 Perspective Life Science Co., Ltd.*** main business by industry.
Chart 2022 Perspective Life Science Co., Ltd.***Main business by region.
Chart 2020-2023 Perspective Life Sciences Co., Ltd.*** operating profit and operating profit margin.
Chart: 2020-2023 Return on equity of Toujing Life Science and Technology shares.
Chart 2020-2023 Short-term solvency indicator of Toujing Life Science and Technology shares.
Chart 2020-2023 Perspective Life Science and Technology Co., Ltd.*** asset-liability ratio level.
Chart 2020-2023 Toujing Life Science Co., Ltd.*** Operational Capability Indicators.
Chart 2020-2023 Kehua Bioengineering Co., Ltd.*** total assets and net assets scale.
Chart 2020-2023 Kehua Bioengineering Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 Kehua Bioengineering Co., Ltd.*** net profit and growth rate.
Chart 2022 Kehua Bioengineering Co., Ltd.*** main business by industry.
Chart 2022 Kehua Bioengineering Co., Ltd.***Main business by region.
Chart 2020-2023 Kehua Bioengineering Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 Kehua Bioengineering shares*** return on net assets.
Chart 2020-2023 Kehua Bioengineering shares*** short-term solvency indicators.
Chart 2020-2023 Kehua Bioengineering Co., Ltd.*** asset-liability ratio level.
Chart 2020-2023 Kehua Bioengineering Co., Ltd. *** operating capacity indicators.
Chart 2020-2023 Kaipu Biotechnology Co., Ltd.*** total assets and net assets scale.
Chart 2020-2023 Kaipu Biotechnology Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 net profit and growth rate of Kaipu Biotechnology Co., Ltd.
Chart 2022 Kaipu Biotechnology Co., Ltd.***Main business by industry.
Chart 2022 Kaipu Biotechnology Co., Ltd.*** main business by region.
Chart 2020-2023 Kaipu Biotechnology Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 return on equity of Kaipu Biotechnology shares.
Chart 2020-2023 Kaipu Biotechnology shares*** short-term solvency indicators.
Chart 2020-2023 Kaipu Biotechnology shares*** asset-liability ratio level.
Chart 2020-2023 Kaipu Biotechnology Co., Ltd. *** Operational Capability Indicators.
Chart 2020-2023 Anke Bioengineering Co., Ltd.*** total assets and net assets scale.
Chart 2020-2023 Anke Bioengineering Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 Anke Bioengineering Co., Ltd.*** net profit and growth rate.
Chart 2022 Anke Bioengineering Co., Ltd.*** main business by industry.
Chart 2022 Anke Bioengineering Co., Ltd.*** main business by region.
Chart 2020-2023 Anke Bioengineering Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 Anke Bioengineering shares*** return on net assets.
Chart 2020-2023 Anke Bioengineering shares*** short-term solvency indicators.
Chart 2020-2023 Anke Bioengineering shares*** asset-liability ratio level.
Chart 2020-2023 Anke Bioengineering Co., Ltd.*** Operational Capability Indicators.
Chart 2020-2023 Zhishan Biotechnology Co., Ltd.*** total assets and net assets scale.
Chart 2020-2023 Zhishan Biotechnology Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 Zhishan Biotechnology Co., Ltd.*** net profit and growth rate.
Chart 2022 Zhishan Biotechnology Co., Ltd.***Main business by industry.
Chart 2022 Zhishan Biotechnology Co., Ltd.*** main business by region.
Chart 2020-2023 Zhishan Biotechnology Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 Return on equity of Zhishan Biotechnology shares***.
Chart 2020-2023 Zhishan Biotechnology shares*** short-term solvency indicator.
Chart 2020-2023 Zhishan Biotechnology shares*** asset-liability ratio level.
Chart 2020-2023 Zhishan Biotechnology Co., Ltd. *** Operational Capability Indicators.
Chart 2009-2020 global investment in the field of molecular diagnostics trend.
Chart Statistics of financing events in China's molecular diagnostics industry in 2020.
Chart 2020 China Molecular Diagnostics Listing Events.
Chart: Investment and financing of nucleic acid testing industry from 2000 to 2021.
Figure Distribution of financing rounds in the nucleic acid testing industry from 2000 to 2021.
Figure 2015-2021 China's biochip-related enterprises financing number and round distribution.
Chart Global Molecular Diagnostics Market Size, 2024-2030**.
Chart 2024-2030 China Molecular Diagnostics Market Size**.